Market capitalization | $1.31b |
Enterprise Value | $1.12b |
P/E (TTM) P/E ratio | 60.85 |
EV/FCF (TTM) EV/FCF | 42.50 |
EV/Sales (TTM) EV/Sales | 3.28 |
P/S ratio (TTM) P/S ratio | 3.85 |
P/B ratio (TTM) P/B ratio | 3.07 |
Revenue growth (TTM) Revenue growth | 10.01% |
Revenue (TTM) Revenue | $341.22m |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
12 Analysts have issued a STAAR Surgical Company forecast:
12 Analysts have issued a STAAR Surgical Company forecast:
Sep '24 |
+/-
%
|
||
Revenue | 341 341 |
10%
10%
|
|
Gross Profit | 269 269 |
11%
11%
|
|
EBITDA | 32 32 |
31%
31%
|
EBIT (Operating Income) EBIT | 26 26 |
38%
38%
|
Net Profit | 22 22 |
12%
12%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
STAAR Surgical Co. engages in the development, manufacture, production, marketing, and sale of implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. It specializes in refractive and cataract solutions. Its products include intraocular lens and implantable collamer lens. The company was founded in 1982 and is headquartered in Lake Forest, CA.
Head office | United States |
CEO | Thomas Frinzi |
Employees | 1,115 |
Founded | 1982 |
Website | www.staar.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.